Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Breast 7 Gastrointestinal 6 Tumor-Agnostic 4 Head & Neck 4 Thoracic 3 Myeloid 3 Dermatologic 3 Other hematologic neoplasm 2 Lymphoid 2 Genitourinary 2 Other neoplasm 1 NET 1 Endocrine 1 Classical hematology 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

Specimen Handling 13 Magnetic Resonance Spectroscopy 13 lutetium Lu 177 dotatate 8 cabozantinib 6 Nivolumab 5 X-Rays 4 Ipilimumab 4 Cisplatin 4 pembrolizumab 3 fludarabine 3 Phantoms, Imaging 3 Everolimus 3 Etoposide 3 Cyclophosphamide 3 Carboplatin 3 CTLA-4 Antigen 3 olaparib 2 gallium Ga 68 dotatate 2 fluorodopa F 18 2 aldesleukin 2 Lutetium-177 2 Lutetium 2 Irinotecan 2 Fluorodeoxyglucose F18 2 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 2 trametinib 1 tipifarnib 1 sodium thiosulfate 1 selpercatinib 1 repotrectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Blood Specimen Collection × Endocrine × 30 days × Clear all

NCT06430021 2026-05-22

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡